Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer Review
| Authors: | Rubinstein, M.; Shen, S.; Monk, B. J.; Tan, D. S. P.; Nogueira-Rodrigues, A.; Aoki, D.; Sehouli, J.; Makker, V. |
| Review Title: | Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer |
| Abstract: | Endometrial cancer incidence and mortality are rising among all ethnic groups. Carboplatin plus paclitaxel is the established frontline treatment for advanced/recurrent disease; however, subsequent treatment with traditional cytotoxic chemotherapy is challenging. The molecular characterization of endometrial cancer has provided important insights into the biological drivers of carcinogenesis, which has allowed for the development of newer precision immunotherapies and targeted therapies, including pembrolizumab, dostarlimab, and lenvatinib. Until recently, platinum rechallenge was often considered at the time of recurrence, given the lack of other available therapeutic options; however, “platinum sensitivity” in endometrial cancer is subjective and largely based on expert opinion and/or practitioner experience. Small retrospective studies have tried to provide guidance on the utility of platinum rechallenge, but they are limited by variable patient characteristics and small sample sizes. The applicability of these retrospective studies to contemporary clinical practice is difficult in the setting of changing patient demographics, a better understanding of endometrial cancer drivers, and the recent approvals of immune checkpoint inhibitors and the combination of lenvatinib plus pembrolizumab in the second-line setting. The primary focus of this review is to distill the available data regarding platinum-doublet chemotherapy rechallenge and highlight recent pivotal developments in endometrial cancer treatment, as well as future directions. © 2022 Elsevier Inc. |
| Keywords: | cancer chemotherapy; cancer survival; retrospective studies; overall survival; review; cancer recurrence; advanced cancer; cancer combination chemotherapy; paclitaxel; chemotherapy; treatment; endometrial cancer; antineoplastic agent; endometrial neoplasms; endometrium cancer; carboplatin; progression free survival; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; chemosensitivity; retrospective study; cancer resistance; tumor recurrence; recurrent disease; cancer classification; endometrium tumor; platinum sensitivity; humans; human; female; doublet chemotherapy |
| Journal Title: | Gynecologic Oncology |
| Volume: | 167 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-12-01 |
| Start Page: | 540 |
| End Page: | 546 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2022.10.012 |
| PUBMED: | 36280455 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding author is MSK author Sherry Shen -- Export Date: 1 February 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work